Atea Pharmaceuticals (AVIR) Assets Average (2020 - 2026)

Atea Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $291.1 million for Q1 2026.

• On a quarterly basis, Assets Average fell 35.63% year-over-year to $291.1 million in Q1 2026; TTM through Mar 2026 was $291.1 million, a 35.63% decrease from a year earlier, with the FY2025 full-year figure at $389.9 million, down 26.4% from the prior year.
• Assets Average declined to $291.1 million in Q1 2026 per AVIR's latest filing, from $329.1 million in the prior quarter.
• Across five years, Assets Average topped out at $745.0 million in Q1 2022 and bottomed at $291.1 million in Q1 2026.
• The 5-year median for Assets Average is $574.0 million (2024), against an average of $544.8 million.
• Across the five-year window, Assets Average dropped 10.44% in 2023 and sank 35.63% in 2026, its largest moves.
• Year by year, Assets Average stood at $676.6 million in 2022, then declined by 11.1% to $601.5 million in 2023, then dropped by 20.57% to $477.8 million in 2024, then tumbled by 31.13% to $329.1 million in 2025, then fell by 11.53% to $291.1 million in 2026.
• Per Business Quant, the three latest AVIR Assets Average figures stand at $291.1 million (Q1 2026), $329.1 million (Q4 2025), and $367.3 million (Q3 2025).